Phase 1B/2 Study of Lurbinectedin With or Without Irinotecan for Patients With Relapsed or High Risk Chemotherapy-Naive Ewing Sarcoma
Latest Information Update: 14 Feb 2022
At a glance
- Drugs Irinotecan (Primary) ; Lurbinectedin (Primary)
- Indications Ewing's sarcoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 01 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment as PI stated trial no longer fits the framework & portfolio of work that is prioritized by the department. PI will not have the anticipated accrual in PI view to complete the study. Given that, PI request this protocol be closed prior to its activation.
- 17 Sep 2021 New trial record